ArticleTranslational cancer research2025
Integrating single-cell and bulk RNA sequencing data to construct a pyroptosis-related prognostic signature and analyze the tumor microenvironment in gastric cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a prevalent malignancy with high morbidity and mortality. Pyroptosis, a form of programmed cell death, plays a significant role in cancer progression and immune regulation. This study aimed to construct a pyroptosis-related prognostic signature (PRPS) and analyze its association with the tumor microenvironment in GC by integrating single-cell and bulk RNA sequencing data. Methods: Pyroptosis-related differentially expressed genes in GC were identified by integrating single-cell and bulk RNA sequencing data. The PRPS was constructed using univariate and multivariate Cox regression analyses, and evaluated by Kaplan-Meier curves, receiver operating characteristic curves, and nomogram analysis. Subsequently, genomic variations, immune landscapes, immune checkpoint inhibitors (ICIs) responses, and drug sensitivity were evaluated in different risk subgroups. Results: We constructed a PRPS in GC by integrating single-cell and bulk RNA sequencing data. The PRPS exhibited strong predictive efficiency, with the high-risk group showing significantly lower overall survival, progression-free survival, and disease-specific survival. Multivariate Cox regression validated the PRPS as an independent prognostic factor, while the PRPS-based nomogram showed high predictive accuracy. Functional enrichment and immune landscape analysis revealed the differences between the risk subgroups in immune pathways, gene mutations, immune cell infiltration, and tumor mutational burden. Analysis of ICIs responses and drug sensitivity showed the differences in treatment among different risk subgroups, providing a basis for personalized treatment. Conclusions: The PRPS provides a promising tool for the prognostic prediction, targeted prevention, and personalized treatment for GC, and may promote the precision medicine for GC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.